2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association
IVT
Thrombolytic Agent
2018: Alteplase only (standard 0.9 mg/kg)
2026: Tenecteplase (0.25 mg/kg) or alteplase — both Class I recommended
*Tenecteplase 1st-line, if LVO bridging therapy, patients requiring rapid workflow, difficult IV access or prehospital administration
NIHSS and Disability
2018: NIHSS severity emphasized
2026: Any disabling deficit should receive IVT — NIHSS alone should not delay therapy